sNDA Accepted, Priority Review Granted to Tarceva for Genetically Distinct NSCLC

Share this content:

Astellas announced that the FDA has accepted for filing a supplemental New Drug Application (sNDA) for Tarceva (erlotinib) for first-line use in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations; the application has been granted Priority Review status. Erlotinib is a human EGFR type 1/EGFR tyrosine kinase inhibitor.

The sNDA submission is based on results of the international EURTAC trial, a prospective, randomized, controlled Phase 3 trial evaluating the first-line use of Tarceva vs. platinum-based chemotherapy in patients with EGFR activating mutation-positive advanced NSCLC.  A pre-market approval application for a companion diagnostic, the cobas EGFR Mutation Test (developed by Roche), has also been submitted to the FDA.

Tarceva is approved for the maintenance treatment of patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as well as the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Tarceva is also approved in combination with gemcitabine (Gemzar; Lilly) as a first-line treatment of locally advanced, unresectable or metastatic pancreatic cancer.

For more information call (800) 727-7003 or visit www.us.astellas.com

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs